Abstract
TB is rumoured to infect nearly a third of the world's population. The risk of LTBI progression to active TB is clearly heightened by antitumour necrosis factor α (anti-TNF) therapy, and the absolute risk of this complication is driven by the background prevalence of LTBI in a particular region and the probability of infection in an individual. Within low prevalence countries, rates of anti-TNF-associated TB are typically 5–10-fold higher than background general populations, with greater relative risks reported from countries of higher TB prevalence.5–8 Screening for LTBI with the TST prior to anti-TNF start has been associated with decreasing anti-TNF-associated TB incidence, and in the past several years, data suggest that algorithms using IGRAs can assist in identifying infected patients prior to initiation of therapy.1 , 9–12 These tests incorporate antigens with high specificity for TB that most importantly do not cross react with Mycobacterium bovis strains used in BCG vaccine, and they do no cross react with most clinically relevant non-tuberculous mycobacteria (although with several notable exceptions such as Mycobacterium marinum, Mycobacterium kansasii and Mycobacterium szulgai). Accordingly, these tests are of greater specificity for TB, and in populations where BCG has been used, they categorise more accurately which patients are infected.13 Ideally, any optimal screening strategy maximises the number of truly infected persons identified and minimises the number of patients falsely diagnosed with LTBI. However, in immunosuppressive or other high risk settings, we have traditionally (and understandably) favoured sensitivity in screening for LTBI.

This publication has 23 references indexed in Scilit: